Mark A. Hess

2.9k citations

47 papers · 2.0k indexed · h-index 23

Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 37
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 7
Oncology top 5%
- Viral-associated cancers and disorders 12
Neurology top 2%
- CNS Lymphoma Diagnosis and Treatment 15
Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment 5
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 7
Physiology
- Alzheimer's disease research and treatments 2
Immunology and Allergy
- Allergic Rhinitis and Sensitization 2

Co-authors: Fernando Cabanillas Chul S. Ha James D. Cox Patrick C. May Judes Poirier Caleb E. Finch Richard B. Wilder Peter McLaughlin
Cited by: Pathology and Forensic Medicine Genetics Oncology
Journals: International Journal of Radiation Oncology*Biology*Physics (16 papers)Cancer (10 papers)Blood (4 papers)
Partner nations: United States Germany Canada

In The Last Decade

Mark A. Hess

47 papers receiving 2.0k citations

Peers

Countries citing papers authored by Mark A. Hess

Since Specialization

Citations

This map shows the geographic impact of Mark A. Hess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Hess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Hess more than expected).

Fields of papers citing papers by Mark A. Hess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Hess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Hess. The network helps show where Mark A. Hess may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark A. Hess, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark A. Hess Line = papers co-authored together Mark A. Hess links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis Clinical and Translational Allergy ·G Myllylae,Ursula Pieper‐Fürst,Cengizhan Açıkel,Hacer Sahin,隆榊原,Jasvinder A. Singh,Mark A. Hess,Matthew Petersen,L. M. Huertas Guativa,Ralph Mösges	2022	3
2	1‐(3‐Biaryloxy‐2‐oxopropyl)indole‐5‐carboxylic Acids and Related Compounds as Dual Inhibitors of Human Cytosolic Phospholipase A₂α and Fatty Acid Amide Hydrolase ChemMedChem ·韩秀云,E. Epple,Mark A. Hess,Jaqueline Gonzalez Mesa,Matthias Lehr	2011	14
3	1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A2α: Bioisosteric replacement of the carboxylic acid and carboxamide moiety Bioorganic & Medicinal Chemistry ·Mark A. Hess,Jaqueline Gonzalez Mesa,Matthias Lehr	2007	22
4	Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma Cancer ·Maricer P. Escalón,孝司山本,Ying Yang,Mark A. Hess,Pamela L. Walker,Terry L. Smith,Nam H. Dang	2005	169
5	Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease American Journal of Clinical Oncology ·Gregory M. Chronowski,Richard B. Wilder,Larry B. Levy,E. Neely Atkinson,Chul S. Ha,Fredrick B. Hagemeister,İbrahim Barışta,Maria Alma Rodriguez,Andreas H. Sarris,Mark A. Hess,Fernando Cabanillas,James D. Cox	2004	24
6	An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease Cancer ·Gregory M. Chronowski,Richard B. Wilder,Susan L. Tucker,Chul S. Ha,Andreas H. Sarris,Fredrick B. Hagemeister,İbrahim Barışta,Mark A. Hess,Fernando Cabanillas,James D. Cox	2002	35
7	Clinical stage IEA–IIEA orbital lymphomas: outcomes in the era of modern staging and treatment Radiotherapy and Oncology ·Christopher E. Pelloski,Richard B. Wilder,Laurence Haouche-Belkessam,Mark A. Hess,Fernando Cabanillas,James D. Cox	2001	39
8	Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas International Journal of Radiation OncologyBiologyPhysics ·Richard B. Wilder,Vives,Susan L. Tucker,Chul S. Ha,Mark A. Hess,Fernando Cabanillas,James D. Cox	2001	18
9	Localized non‐Hodgkin lymphoma involving the thyroid gland Cancer ·Chul S. Ha,Jose Antonio Fernandez Gutierrez,L. Jeffrey Medeiros,Richard B. Wilder,Mark A. Hess,Fernando Cabanillas,James D. Cox	2001	8
10	Long-term results with radiotherapy for stage I–II follicular lymphomas International Journal of Radiation OncologyBiologyPhysics ·Richard B. Wilder,Dan Jones,Susan L. Tucker,Lillian M. Fuller,Laurence Haouche-Belkessam,Peter McLaughlin,Mark A. Hess,Fernando Cabanillas,James D. Cox	2001	126
11	Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy International Journal of Radiation OncologyBiologyPhysics ·Richard B. Wilder,Susan L. Tucker,Chul S. Ha,Maria Alma Rodriguez,Mark A. Hess,Fernando Cabanillas,James D. Cox	2001	32
12	The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum International Journal of Radiation OncologyBiologyPhysics ·Upkar Hooda,Chul S. Ha,Mark A. Hess,Jorge Romaguera,John T. Manning,Fernando Cabanillas,James D. Cox	2000	22
13	Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III–IV, intermediate grade and large-cell immunoblastic lymphomas International Journal of Radiation OncologyBiologyPhysics ·Pamela J. Schlembach,Richard B. Wilder,Susan L. Tucker,Chul S. Ha,Maria Alma Rodriguez,Mark A. Hess,Fernando Cabanillas,James D. Cox	2000	24
14	Stages I-III Follicular Lymphoma: Role of CT of the Abdomen and Pelvis in Follow-up Studies Radiology ·Chunli Lu,Chul S. Ha,Barry I. Samuels,Fernando Cabanillas,Mark A. Hess,James D. Cox	1999	22
15	Hodgkin’s disease with lymphocyte predominance: long-term results based on current histopathologic criteria International Journal of Radiation OncologyBiologyPhysics ·Chul S. Ha,Vivek S. Kavadi,Meletios Α. Dimopoulos,Frederick Hagemeister,Daniel Isaacs,Lillian M. Fuller,Terry L. Smith,Mark A. Hess,Peter W. McLaughlin,Fernando Cabanillas,James D. Cox	1999	16
16	Localized Primary Non-Hodgkin Lymphoma of the Breast American Journal of Clinical Oncology ·Chul S. Ha,Praveen Kumar Dubey,Lav K. Goyal,Mark A. Hess,Fernando Cabanillas,James D. Cox	1998	63
17	Subdiaphragmatic stage I & II Hodgkin’s disease: long-term follow-up and prognostic factors International Journal of Radiation OncologyBiologyPhysics ·Rodney J. Holmes,Chul S. Ha,Lillian M. Fuller,Fredrick B. Hagemeister,Fernando Cabanillas,Susan L. Tucker,Mark A. Hess,James D. Cox	1998	18
18	Long-term outcome of treatment for ann arbor Stage I Hodgkin's disease: Prognostic factors for survival and freedom from progression International Journal of Radiation OncologyBiologyPhysics ·María T. Vlachaki,Frederick Hagemeister,Lillian M. Fuller,Pelayo Besa,Mark A. Hess,(unknown),Fernando Cabanillas,James D. Cox	1997	10
19	Localized primary malignant lymphoma of bone International Journal of Radiation OncologyBiologyPhysics ·Praveen Kumar Dubey,Chul S. Ha,Pelayo Besa,Lillian M. Fuller,Fernando Cabanillas,John Murray,Mark A. Hess,James D. Cox	1997	84
20	Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning Molecular Brain Research ·Judes Poirier,Mark A. Hess,Patrick C. May,Caleb E. Finch	1991	327

About Mark A. Hess

Mark A. Hess is a scholar working on Pathology and Forensic Medicine, Neurology, Genetics, Reproductive Medicine and Oncology, having authored 47 papers that have together received 2.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (37 papers), CNS Lymphoma Diagnosis and Treatment (15 papers), Viral-associated cancers and disorders (12 papers), Chronic Lymphocytic Leukemia Research (7 papers), Lung Cancer Treatments and Mutations (7 papers), Ovarian cancer diagnosis and treatment (5 papers), Alzheimer's disease research and treatments (2 papers) and Allergic Rhinitis and Sensitization (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.4k citations), Genetics (343 citations), Oncology (824 citations), Neurology (455 citations) and Reproductive Medicine (118 citations). Mark A. Hess has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Fernando Cabanillas, Chul S. Ha, James D. Cox, Patrick C. May, Judes Poirier, Caleb E. Finch, Richard B. Wilder, Peter McLaughlin, Maria Alma Rodriguez and Susan L. Tucker. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Cancer, Blood, Journal of Clinical Oncology and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact